The injection is an auto-injector system for subcutaneous use. It is a therapeutic equivalent generic version of Imitrex Statdose Pen (sumatriptan succinate) and was launched in the US market today ...
SAN FRANCISCO — The sumatriptan 3-mg subcutaneous auto-injector (Zembrace SymTouch, Promius Pharma) approved by the US Food and Drug Administration (FDA) for acute treatment of episodic migraine, with ...
Dr. Reddy’s Laboratories announced the launch of Sumatriptan Injection Autoinjector System for Subcutaneous Use, the generic version of GlaxoSmithKline‘s Imitrex STATdose Pen. Sumatriptan is a ...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous Use, a ...
EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the ...
Meridian Medical has made available Alsuma (sumatriptan injection auto-injector), a selective 5-HT1B/1D receptor agonist, for the acute treatment of migraine attacks, with or without aura, and the ...
Dr Reddy’s Laboratories announced on today that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL, for subcutaneous use in the US market on February 25. It is a therapeutic ...
The US Food and Drug Administration (FDA) has approved Antares Pharma, Inc's Abbreviated New Drug Application (ANDA) for 4 mg/0.5 ml and 6 mg/0.5 ml Sumatriptan injection USP in adults for the acute ...
Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results